For more information, visit Basuch.com Important Risk Information Prescribing Information Visit Zirgan's website

HSV Keratitis Post-LASIK

Case Study #6

A 58-year-old male presents three months post-LASIK with blurred vision and some mild to moderate discomfort in the right eye. Clinical examination shows a classic dendritic ulcer. Dr. Mile Brujic shares the details of this case and talks about managing herpetic keratitis with ZIRGAN (ganciclovir ophthalmic gel) 0.15%.

  • Bookmark
  • QuickLink

Indication ZIRGAN® is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Risk Information about ZIRGAN®

  • ZIRGAN® is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN®.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Please see the full prescribing information for ZIRGAN® here.

For more information about treating herpes simplex epithelial keratitis with ZIRGAN®, click here.

ZIRGAN is a registered trademark of Laboratoires Théa Corporation licensed by Bausch & Lomb Incorporated.

©2012 Bausch & Lomb Incorporated.
PH4427 2/12

Comments (0)